Cited by 220Asthma and respiratory diseasesOccupational exposure and asthmaChronic Obstructive Pulmonary Disease (COPD) Research

Management of severe asthma in children

Open access
Bush, Andrew, Saglani, Sejal·2010·The Lancet

Abstract

Children who are referred to specialist care with asthma that does not respond to treatment (problematic severe asthma) are a heterogeneous group, with substantial morbidity. The evidence base for management is sparse, and is mostly based on data from studies in children with mild and moderate asthma and on extrapolation of data from studies in adults with severe asthma. In many children with severe asthma, the diagnosis is wrong or adherence to treatment is poor. The first step is a detailed diagnostic assessment to exclude an alternative diagnosis ("not asthma at all"), followed by a multidisciplinary approach to exclude comorbidities ("asthma plus") and to assess whether the child has difficult asthma (improves when the basic management needs, such as adherence and inhaler technique, are corrected) or true, therapy-resistant asthma (still symptomatic even when the basic management needs are resolved). In particular, environmental causes of secondary steroid resistance should be identified. An individualised treatment plan should be devised depending on the clinical and pathophysiological characterisation. Licensed therapeutic approaches include high-dose inhaled steroids, the Symbicort maintenance and reliever (SMART) regimen (with budesonide and formoterol fumarate), and anti-IgE therapy. Unlicensed treatments include methotrexate, azathioprine, ciclosporin, and subcutaneous terbutaline infusions. Paediatric data are needed on cytokine-specific monoclonal antibody therapies and bronchial thermoplasty. However, despite the interest in innovative approaches, getting the basics right in children with apparently severe asthma will remain the foundation of management for the foreseeable future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(10)61054-9

Cites

192 of 192 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The limitation of the use of maximum treatment is that there may be different reasons for poor asthma control among patients on maximum treatment, such as wrong diagnosis, non-adherence with medication, or therapy-resistant disease.

    “The limitation of the use of “maximum treatment” is that there may be different reasons for poor asthma control among patients on “maximum treatment,” such as the wrong diagnosis (46), non-adherence with medication (50), or therapy-resistant disease (48).”

    From Epidemiology of Asthma in Children and Adults (2019) · cites this paper as [48]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [118]Adams NP Bestall JC Jones P Lasserson TJ Griffiths B Cates CJ Fluticasone at different doses for chronic asthma in adults and children Cochrane Database Syst Rev 2008 4 CD003534 18843646 PMC6984662

Cited by

Sorted by citations

Authors
Bush, A., & Saglani, S.
Affiliations
Royal Brompton Hospital (GB)
Corresponding author
Bush, Andrew
Venue
The Lancet
Publisher
Elsevier BV
Published
2010-09
Volume
376
Issue
9743
Pages
814-825
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2137995619
Cited by
220
References
192
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 6 · 2022: 10 · 2021: 9 · 2020: 12 · 2019: 21 · 2018: 18 · 2017: 25 · 2016: 12 · 2015: 11 · 2014: 12 · 2013: 21 · 2012: 28
FWCI
2.44
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Wellcome Trust (083586)
  • National Institute for Health and Care Research (NF-SI-0508-10212)
Topics
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Occupational exposure and asthma
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
severe asthma, childhood asthma, treatment-resistant asthma, steroid resistance, inhaler technique, medication adherence, asthma comorbidity, difficult-to-treat asthma, high-dose inhaled corticosteroids, budesonide/formoterol, anti-IgE therapy, methotrexate, cyclosporine, bronchial thermoplasty, asthma diagnosis
MeSH terms
Formoterol Fumarate, Budesonide, Formoterol Fumarate Drug Combination, Administration, Inhalation, Adrenal Cortex Hormones, Allergens, Asthma, Azathioprine, Bronchial Provocation Tests, Bronchodilator Agents, Child, Clinical Trials as Topic, Drug Combinations, Drug Therapy, Combination, Eosinophils, Ethanolamines, House Calls, Humans, Immunoglobulin E, Methotrexate, Risk Factors, Severity of Illness Index, Spirometry, Terbutaline, Tobacco Smoke Pollution, Tomography, X-Ray Computed, Comorbidity, Cyclosporine, Treatment Outcome, Drug Resistance, Multiple, Anti-Asthmatic Agents, Budesonide, Interdisciplinary Communication, Off-Label Use

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review